P-112 ADVANCED FIBROSIS IN PATIENTS WITH LIVER STEATOSIS MEASURED BY FIBROSCAN AND ITS ASSOCIATED FACTORS

Conflict of interest

No

Introduction and Objectives

The prevalence of fatty liver disease associated with metabolic dysfunction (MASLD) has been increasing. Its most advanced stage is F3-F4 fibrosis with eventual decompensation and the need for liver transplantation. The aim was to identify the factors associated with advanced fibrosis as observed by liver elastography (Fibroscan®) in patients with MASLD and in a subgroup of patients with diabetes mellitus (DM).

Patients / Materials and Methods

Retrospective, descriptive study of patients with MASLD who underwent Fibroscan® in our center between October 2023 and June 2024. Patients were categorized into 2 groups: without advanced fibrosis (F0-F2) and with advanced fibrosis (F3-F4). Sociodemographic variables, clinical and laboratory history were analyzed between groups, using chi2 and Mann-Whitney in Stata 16.0 software.

Results and Discussion

Of 1297 Fibroscan® performed in the study period, 577 (44%) patients met MASLD criteria for analysis; 62% women, median age 58 years (interquartile range 48 – 66); Advanced fibrosis was presented in 132 (33%) patients. The table compares the sociodemographic and clinical characteristics of the patients according to the degree of fibrosis. Older age, Fonasa health insurance, hypertension, diabetes mellitus, obesity, higher level of glycosylated hemoglobin and higher CAP (Coefficient Attenuated Parameter) were associated with advanced fibrosis. A sub-analysis was carried out in patients with MASLD and DM (n = 151), observing that Fonasa health insurance (65% vs 47%; p=0.032) and obesity (67% vs 43%; p=0.004) were associated with advanced fibrosis.

Conclusions

In patients with MASLD who present cardio metabolic risk factors such as older age, hypertension, diabetes mellitus, and obesity, the presence of advanced fibrosis should be evaluated to prevent associated complications.